ZA201801134B - Hydroxytriazine compound and medical use thereof - Google Patents

Hydroxytriazine compound and medical use thereof

Info

Publication number
ZA201801134B
ZA201801134B ZA2018/01134A ZA201801134A ZA201801134B ZA 201801134 B ZA201801134 B ZA 201801134B ZA 2018/01134 A ZA2018/01134 A ZA 2018/01134A ZA 201801134 A ZA201801134 A ZA 201801134A ZA 201801134 B ZA201801134 B ZA 201801134B
Authority
ZA
South Africa
Prior art keywords
medical use
hydroxytriazine
compound
hydroxytriazine compound
medical
Prior art date
Application number
ZA2018/01134A
Other languages
English (en)
Inventor
Mitani Ikuo
Hirono Yutaro
Yamashita Masaki
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of ZA201801134B publication Critical patent/ZA201801134B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2018/01134A 2015-08-17 2018-02-19 Hydroxytriazine compound and medical use thereof ZA201801134B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015160284 2015-08-17
PCT/JP2016/073879 WO2017030115A1 (ja) 2015-08-17 2016-08-16 ヒドロキシトリアジン化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
ZA201801134B true ZA201801134B (en) 2019-07-31

Family

ID=58052084

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/01134A ZA201801134B (en) 2015-08-17 2018-02-19 Hydroxytriazine compound and medical use thereof

Country Status (19)

Country Link
US (3) US20170057943A1 (enExample)
EP (2) EP3339296A4 (enExample)
JP (4) JP2017039714A (enExample)
KR (1) KR20180037270A (enExample)
CN (1) CN108137515B (enExample)
AR (1) AR105711A1 (enExample)
AU (1) AU2016309337B2 (enExample)
BR (1) BR112018001809A2 (enExample)
CA (1) CA2992410A1 (enExample)
CL (1) CL2018000430A1 (enExample)
CO (1) CO2018002516A2 (enExample)
IL (1) IL257559B (enExample)
MX (1) MX375283B (enExample)
PE (1) PE20180951A1 (enExample)
PH (1) PH12018500181A1 (enExample)
SG (1) SG11201800698VA (enExample)
TW (1) TWI704139B (enExample)
WO (1) WO2017030115A1 (enExample)
ZA (1) ZA201801134B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI651310B (zh) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
EP3339296A4 (en) * 2015-08-17 2019-01-23 Japan Tobacco, Inc. HYDROXYTRIAZINE COMPOUND AND USE THEREOF IN MEDICINE
AU2016346557B2 (en) * 2015-10-29 2020-10-29 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative
RU2648181C1 (ru) * 2017-05-25 2018-03-22 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения нейроретинопатии вследствие тяжелой преэклампсии
CN110799506B (zh) * 2017-06-26 2024-03-01 默克专利有限公司 用于制备被取代的含氮杂环化合物的方法
EP4553068A1 (en) * 2022-07-06 2025-05-14 ASKA Pharmaceutical Co., Ltd. Pyrimidine derivatives

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH473818A (de) 1964-03-18 1969-06-15 Ciba Geigy Verfahren zur Herstellung von neuen Hydroxyphenyl-1,3,5-triazinen und deren Verwendung
SU1313854A1 (ru) 1985-04-17 1987-05-30 Институт Органической Химии Ан Армсср Способ получени смеси 2-оксо-2,3-дигидро-4,6,-бис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина и 2,4,6-трис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина
DE19543730A1 (de) 1995-11-23 1997-05-28 Ciba Geigy Ag Bis-Resorcinyl-Triazine
JP2002514195A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
ZA9710727B (en) 1996-12-05 1998-06-12 Amgen Inc Substituted pyrimidine compounds and methods of use.
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
TR200102810T2 (tr) 1999-04-01 2002-01-21 Pfizer Products Inc. Sorbitol dehidrojenaz inhibitörleri olarak aminopirimidinler
KR101538811B1 (ko) 2007-04-03 2015-07-22 이 아이 듀폰 디 네모아 앤드 캄파니 치환된 벤젠 살진균제
BRPI0913343B1 (pt) 2008-06-04 2018-01-23 Adeka Corporation Método para produção do composto 2,4,6-tri (hidroxifenil)-1,3,5-triazina
JP5388270B2 (ja) 2008-06-04 2014-01-15 株式会社Adeka 2,4,6−トリス(ヒドロキシフェニル)−1,3,5−トリアジン化合物の製造方法
EP2138488A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
CN101747282A (zh) * 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
AU2010298720B2 (en) * 2009-09-23 2015-07-23 Albert Einstein College Of Medicine, Inc. Prostaglandin transporter inhibitors and uses thereof
WO2011048004A1 (en) 2009-10-23 2011-04-28 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin e2 synthase-1
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
AR086254A1 (es) 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
FR2983859B1 (fr) 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
AU2013265266A1 (en) 2012-05-23 2015-01-15 Stemergie Biotechnology Sa Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲mPGES-1抑制劑之三唑酮化合物
WO2015059618A1 (en) * 2013-10-22 2015-04-30 Glenmark Pharmaceuticals S.A. SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
CN105586773A (zh) 2014-11-13 2016-05-18 东丽纤维研究所(中国)有限公司 一种拒水抗紫外纺织品及其生产方法和用途
EP3339296A4 (en) * 2015-08-17 2019-01-23 Japan Tobacco, Inc. HYDROXYTRIAZINE COMPOUND AND USE THEREOF IN MEDICINE

Also Published As

Publication number Publication date
AU2016309337B2 (en) 2021-03-04
JP2022163169A (ja) 2022-10-25
BR112018001809A2 (pt) 2018-09-18
US20210024486A1 (en) 2021-01-28
US12492182B2 (en) 2025-12-09
CN108137515B (zh) 2021-07-06
CN108137515A (zh) 2018-06-08
JP7640658B2 (ja) 2025-03-05
PE20180951A1 (es) 2018-06-11
US20240076278A1 (en) 2024-03-07
SG11201800698VA (en) 2018-03-28
RU2018109220A (ru) 2019-09-19
MX375283B (es) 2025-03-06
WO2017030115A1 (ja) 2017-02-23
TWI704139B (zh) 2020-09-11
MX2018002044A (es) 2018-04-13
RU2018109220A3 (enExample) 2019-11-15
IL257559A (en) 2018-04-30
US20170057943A1 (en) 2017-03-02
CA2992410A1 (en) 2017-02-23
EP3339296A1 (en) 2018-06-27
JP2024019449A (ja) 2024-02-09
EP4046991A1 (en) 2022-08-24
AR105711A1 (es) 2017-11-01
CL2018000430A1 (es) 2018-08-03
CO2018002516A2 (es) 2018-05-31
PH12018500181A1 (en) 2018-07-30
TW201718524A (zh) 2017-06-01
JP2020193235A (ja) 2020-12-03
IL257559B (en) 2021-07-29
KR20180037270A (ko) 2018-04-11
AU2016309337A1 (en) 2018-02-01
JP2017039714A (ja) 2017-02-23
EP3339296A4 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
IL254552A0 (en) Polycyclic carbamoylpyridone compounds and their pharmaceutical uses
IL247072A0 (en) Medical use
SG11201707816PA (en) Patient interface and aspects thereof
ZA201606449B (en) Triazine compound and use thereof for medical purposes
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
ZA201802256B (en) Compounds and therapeutic uses thereof
ZA201801134B (en) Hydroxytriazine compound and medical use thereof
IL250729A0 (en) A pyrazolothiazole compound and a drug containing it
PT3129398T (pt) Novos agentes médicos e usos dos mesmos
GB201420805D0 (en) Ligatures and use thereof
IL265617B (en) 1-phenylpropanone compounds and their use
GB201713975D0 (en) Medical use
GB2545167B (en) Cloches and use thereof
GB201514770D0 (en) Compounds and their use
GB201504770D0 (en) Medical devices and methods
GB201513318D0 (en) Novel compounds and their use
GB201508290D0 (en) Medical devices